NASDAQ$EOLS
Evolus Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Evolus reported record Q4 2021 sales of Jeuveau, reflecting accelerating growth trends.
Evolus reported a strong fourth quarter and full-year 2021, with Q4 net revenue increasing by 68% to $34.7 million compared to Q4 2020. The company's full-year net revenue grew by 76% to $99.7 million. Evolus is confident in its 2022 net revenue guidance of $143 million to $150 million.
- Q4 2021 net revenue reached $34.7 million, a 68% increase from Q4 2020.
- Full-year 2021 net revenue grew by 76% to $99.7 million compared to 2020.
- Evolus added 400 new customer accounts in Q4 2021 and 1,400 new accounts in 2021, bringing the total accounts purchasing since launch to more than 7,000.
- Cash position at December 31, 2021, was $146.3 million.
Headline financials
Revenue & EPS history
Evolus · Revenue · Quarterly
$34.7M
Forward guidance
Evolus expects total net revenues for full-year 2022 to be between $143 million and $150 million, representing strong year-over-year growth of 43% to 50%.
Tailwinds
- Total net revenues for full-year 2022 to be between $143 million and $150 million, representing strong year-over-year growth of 43% to 50%.
- Adjusted gross profit margin for the full year 2022 to be between 58% and 61%.
- Settlement royalty rates will decrease significantly in September 2022, which is expected to lift the adjusted gross profit margin to be between 68% to 71% for the fourth quarter of 2022.
- The company remains on track to commence the launch of Nuceiva® in Europe in the third quarter of 2022.
- Continue investments in the growth of Jeuveau® in the U.S. plus Nuceiva® launch expenses in Europe.
Headwinds
- During the first quarter of 2022, the company expects to make its second lump-sum settlement payment of $15 million under the 2021 settlement agreements.
- The company will make its final settlement payment of $5 million in the first quarter of 2023.
- Non-GAAP operating expenses for 2022 are estimated to be between $135 million and $140 million.
- Assumes a minimal sales contribution from international markets.
- Settlement royalty rates will impact gross profit margin until September 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.5%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+35.4%
Q4 2025
Best reaction
-26.9%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | +19.3% | — | |
| Q4 2025 | +35.4% | +29.5% | -2.4% | |
| Q3 2025 | +5.4% | +2.6% | +0.6% | |
| Q1 2025 | -14.2% | -13.9% | -14.6% | |
| Q4 2024 | -1.3% | -11.6% | -25.5% | |
| Q3 2024 | -13.3% | -20.4% | -23.2% | |
| Q2 2024 | +15.2% | +9.2% | +30.4% | |
| Q1 2024 | -1.0% | -4.8% | -7.4% | |
| Q4 2023 | -0.3% | -0.1% | -6.0% | |
| Q3 2023 | +9.7% | +0.4% | +20.3% | |
| Q2 2023 | -1.2% | -8.3% | -2.6% | |
| Q1 2023 | +17.8% | +14.9% | -3.9% | |
| Q4 2022 | -6.4% | -7.7% | -8.5% | |
| Q3 2022 | -8.4% | -3.2% | -1.6% | |
| Q2 2022 | -26.9% | -28.3% | -30.3% | |
| Q1 2022 | +9.2% | +29.0% | +20.4% | |
| Q4 2021 | +1.8% | +3.0% | +25.0% | |
| Q3 2021 | -9.5% | -10.0% | -33.3% | |
| Q2 2021 | -6.9% | +1.7% | -15.1% | |
| Q1 2021 | -0.9% | +2.4% | +41.1% | |
| Q4 2020 | -21.1% | -28.2% | -43.0% | |
| Q3 2020 | -1.9% | +2.3% | +23.9% | |
| Q2 2020 | +6.6% | +6.0% | +2.6% | |
| Q1 2020 | +4.8% | -9.7% | +32.9% | |
| Q4 2019 | -3.4% | -8.1% | -51.9% | |
| Q3 2019 | -2.2% | -10.7% | -20.3% | |
| Q2 2019 | -10.9% | -21.8% | -6.7% | |
| Q1 2019 | -7.5% | -5.1% | -46.4% | |
| Q4 2018 | +7.0% | -3.3% | -2.7% | |
| Q3 2018 | -5.8% | -6.6% | -10.6% | |
| Q2 2018 | +6.0% | +8.2% | +34.8% | |
| Q1 2018 | +27.9% | +38.9% | +142.4% | |
| Q4 2017 | +8.5% | +9.1% | -15.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro